South Korea · Delayed Price · Currency is KRW CJ Bioscience Statistics
Total Valuation
CJ Bioscience has a market cap or net worth of KRW 62.71 billion. The enterprise value is 29.20 billion.
| Market Cap | 62.71B |
| Enterprise Value | 29.20B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CJ Bioscience has 13.07 million shares outstanding. The number of shares has increased by 27.31% in one year.
| Current Share Class | 13.07M |
| Shares Outstanding | 13.07M |
| Shares Change (YoY) | +27.31% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.54% |
| Owned by Institutions (%) | 0.01% |
| Float | 4.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.60 |
| PB Ratio | 1.30 |
| P/TBV Ratio | 1.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.22.
| Current Ratio | 3.54 |
| Quick Ratio | 3.46 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.53 |
| Interest Coverage | -41.65 |
Financial Efficiency
Return on equity (ROE) is -38.42% and return on invested capital (ROIC) is -21.10%.
| Return on Equity (ROE) | -38.42% |
| Return on Assets (ROA) | -19.14% |
| Return on Invested Capital (ROIC) | -21.10% |
| Return on Capital Employed (ROCE) | -45.20% |
| Weighted Average Cost of Capital (WACC) | 5.29% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.05 |
| Inventory Turnover | 13.88 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.12% in the last 52 weeks. The beta is 0.22, so CJ Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -47.12% |
| 50-Day Moving Average | 6,647.50 |
| 200-Day Moving Average | 8,471.88 |
| Relative Strength Index (RSI) | 30.79 |
| Average Volume (20 Days) | 27,689 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CJ Bioscience had revenue of KRW 3.56 billion and -23.00 billion in losses. Loss per share was -1,760.74.
| Revenue | 3.56B |
| Gross Profit | 591.65M |
| Operating Income | -23.53B |
| Pretax Income | -23.00B |
| Net Income | -23.00B |
| EBITDA | -19.64B |
| EBIT | -23.53B |
| Loss Per Share | -1,760.74 |
Balance Sheet
The company has 44.13 billion in cash and 10.61 billion in debt, with a net cash position of 33.52 billion or 2,565.39 per share.
| Cash & Cash Equivalents | 44.13B |
| Total Debt | 10.61B |
| Net Cash | 33.52B |
| Net Cash Per Share | 2,565.39 |
| Equity (Book Value) | 48.11B |
| Book Value Per Share | 3,682.33 |
| Working Capital | 33.06B |
Cash Flow
In the last 12 months, operating cash flow was -19.84 billion and capital expenditures -10.66 million, giving a free cash flow of -19.85 billion.
| Operating Cash Flow | -19.84B |
| Capital Expenditures | -10.66M |
| Depreciation & Amortization | 3.89B |
| Net Borrowing | -1.09B |
| Free Cash Flow | -19.85B |
| FCF Per Share | -1,519.00 |
Margins
| Gross Margin | 16.61% |
| Operating Margin | -660.47% |
| Pretax Margin | -645.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CJ Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.31% |
| Shareholder Yield | -27.31% |
| Earnings Yield | -36.68% |
| FCF Yield | -31.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CJ Bioscience has an Altman Z-Score of 0.63 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.63 |
| Piotroski F-Score | 3 |